Last updated: 2 August 2024 at 4:45pm EST

Joseph Belanoff Net Worth




The estimated Net Worth of Joseph K Belanoff is at least $34.4 Million dollars as of 31 July 2024. Joseph Belanoff owns over 450,000 units of Corcept Therapeutics Inc stock worth over $28,397,731 and over the last 20 years he sold CORT stock worth over $1,047,145. In addition, he makes $4,958,970 as President, Chief Executive Officer, and Director at Corcept Therapeutics Inc.

Joseph Belanoff CORT stock SEC Form 4 insiders trading

Joseph has made over 75 trades of the Corcept Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 450,000 units of CORT stock worth $1,480,500 on 31 July 2024.

The largest trade he's ever made was exercising 800,000 units of Corcept Therapeutics Inc stock on 6 July 2022 worth over $1,664,000. On average, Joseph trades about 47,165 units every 79 days since 2004. As of 31 July 2024 he still owns at least 798,811 units of Corcept Therapeutics Inc stock.

You can see the complete history of Joseph Belanoff stock trades at the bottom of the page.





Joseph Belanoff biography

Dr. Joseph K. Belanoff M.D. serves as President, Chief Executive Officer, Director of the Company. He is a co-founder of our company and has served as a member of our Board and our Chief Executive Officer since Corcept’s inception in 1999, and as our President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions in the Department of Psychiatry and Behavioral Sciences since 1992. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University’s College of Physicians & Surgeons. Dr. Belanoff brings to our Board a deep knowledge of our research and development programs and commercial operations. He also has expertise in drug discovery and development and clinical medicine.

What is the salary of Joseph Belanoff?

As the President, Chief Executive Officer, and Director of Corcept Therapeutics Inc, the total compensation of Joseph Belanoff at Corcept Therapeutics Inc is $4,958,970. There are no executives at Corcept Therapeutics Inc getting paid more.



How old is Joseph Belanoff?

Joseph Belanoff is 62, he's been the President, Chief Executive Officer, and Director of Corcept Therapeutics Inc since 2014. There are 5 older and 13 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.

What's Joseph Belanoff's mailing address?

Joseph's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Corcept Therapeutics Inc

Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson, and Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.



What does Corcept Therapeutics Inc do?

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis



Complete history of Joseph Belanoff stock trades at Corcept Therapeutics Inc

Insider
Trans.
Transaction
Total value
Joseph K Belanoff
Chief Executive Officer
Option $1,480,500
31 Jul 2024
Joseph K Belanoff
Chief Executive Officer
Option $1,664,000
6 Jul 2022
Joseph K Belanoff
Chief Executive Officer
Option $3,536,000
22 Jan 2021
Joseph K Belanoff
Chief Executive Officer
Option $931,633
20 Mar 2019
Joseph K Belanoff
Chief Executive Officer
Option $258,367
12 Dec 2018
Joseph K Belanoff
Chief Executive Officer
Option $750,000
10 Nov 2016
Joseph K Belanoff
Chief Executive Officer
Option $750,000
7 Nov 2016
Joseph K Belanoff
Chief Executive Officer
Sale $8,700
17 Nov 2006
Joseph K Belanoff
Chief Executive Officer
Sale $4,050
27 Oct 2006
Joseph K Belanoff
Chief Executive Officer
Sale $2,268
25 Oct 2006
Joseph K Belanoff
Chief Executive Officer
Sale $1,633
13 Oct 2006
Joseph K Belanoff
Chief Executive Officer
Sale $4,300
22 Sep 2006
Joseph K Belanoff
Chief Executive Officer
Sale $1,976
22 Sep 2006
Joseph K Belanoff
Chief Executive Officer
Sale $3,751
13 Sep 2006
Joseph K Belanoff
Chief Executive Officer
Sale $10,229
29 Aug 2006
Joseph K Belanoff
Chief Executive Officer
Sale $360
22 Aug 2006
Joseph K Belanoff
Chief Executive Officer
Sale $6,868
10 Aug 2006
Joseph K Belanoff
Chief Executive Officer
Sale $21,566
27 Jul 2006
Joseph K Belanoff
Chief Executive Officer
Sale $7,843
21 Jul 2006
Joseph K Belanoff
Chief Executive Officer
Sale $10,500
10 Jul 2006
Joseph K Belanoff
Chief Executive Officer
Sale $13,728
29 Jun 2006
Joseph K Belanoff
Chief Executive Officer
Sale $11,367
27 Jun 2006
Joseph K Belanoff
Chief Executive Officer
Sale $18,520
20 Jun 2006
Joseph K Belanoff
Chief Executive Officer
Sale $12,150
31 May 2006
Joseph K Belanoff
Chief Executive Officer
Sale $15,175
11 May 2006
Joseph K Belanoff
Chief Executive Officer
Sale $26,650
2 May 2006
Joseph K Belanoff
Chief Executive Officer
Sale $37,514
24 Apr 2006
Joseph K Belanoff
Chief Executive Officer
Sale $12,456
3 Apr 2006
Joseph K Belanoff
Chief Executive Officer
Sale $8,946
30 Mar 2006
Joseph K Belanoff
Chief Executive Officer
Sale $11,523
27 Mar 2006
Joseph K Belanoff
Chief Executive Officer
Sale $13,150
16 Mar 2006
Joseph K Belanoff
Chief Executive Officer
Sale $12,525
15 Mar 2006
Joseph K Belanoff
Chief Executive Officer
Sale $4,662
3 Mar 2006
Joseph K Belanoff
Chief Executive Officer
Sale $7,350
28 Feb 2006
Joseph K Belanoff
Chief Executive Officer
Sale $3,863
23 Feb 2006
Joseph K Belanoff
Chief Executive Officer
Sale $7,725
17 Feb 2006
Joseph K Belanoff
Chief Executive Officer
Sale $6,813
6 Feb 2006
Joseph K Belanoff
Chief Executive Officer
Sale $26,050
1 Feb 2006
Joseph K Belanoff
Chief Executive Officer
Sale $2,841
30 Jan 2006
Joseph K Belanoff
Chief Executive Officer
Sale $20,886
23 Jan 2006
Joseph K Belanoff
Chief Executive Officer
Sale $21,100
18 Jan 2006
Joseph K Belanoff
Chief Executive Officer
Sale $12,540
28 Dec 2005
Joseph K Belanoff
Chief Executive Officer
Sale $7,622
27 Dec 2005
Joseph K Belanoff
Chief Executive Officer
Sale $12,600
22 Dec 2005
Joseph K Belanoff
Chief Executive Officer
Sale $8,400
14 Dec 2005
Joseph K Belanoff
Chief Executive Officer
Sale $12,325
31 Oct 2005
Joseph K Belanoff
Chief Executive Officer
Sale $37,725
21 Oct 2005
Joseph K Belanoff
Chief Executive Officer
Sale $7,987
30 Sep 2005
Joseph K Belanoff
Chief Executive Officer
Sale $17,342
28 Sep 2005
Joseph K Belanoff
Chief Executive Officer
Sale $24,070
16 Sep 2005
Joseph K Belanoff
Chief Executive Officer
Sale $6,466
13 Sep 2005
Joseph K Belanoff
Chief Executive Officer
Sale $22,400
25 Aug 2005
Joseph K Belanoff
Chief Executive Officer
Sale $33,741
15 Aug 2005
Joseph K Belanoff
Chief Executive Officer
Sale $4,382
10 Aug 2005
Joseph K Belanoff
Chief Executive Officer
Sale $15,175
28 Jul 2005
Joseph K Belanoff
Chief Executive Officer
Sale $14,750
25 Jul 2005
Joseph K Belanoff
Chief Executive Officer
Sale $28,750
7 Jul 2005
Joseph K Belanoff
Chief Executive Officer
Sale $26,833
17 Jun 2005
Joseph K Belanoff
Chief Executive Officer
Sale $26,353
14 Jun 2005
Joseph K Belanoff
Chief Executive Officer
Sale $12,600
17 May 2005
Joseph K Belanoff
Chief Executive Officer
Sale $29,120
12 May 2005
Joseph K Belanoff
Chief Executive Officer
Sale $28,875
25 Apr 2005
Joseph K Belanoff
Chief Executive Officer
Sale $10,000
21 Apr 2005
Joseph K Belanoff
Chief Executive Officer
Sale $13,770
28 Mar 2005
Joseph K Belanoff
Chief Executive Officer
Sale $15,319
22 Mar 2005
Joseph K Belanoff
Chief Executive Officer
Sale $12,725
11 Mar 2005
Joseph K Belanoff
Chief Executive Officer
Sale $6,375
4 Mar 2005
Joseph K Belanoff
Chief Executive Officer
Sale $22,400
18 Feb 2005
Joseph K Belanoff
Chief Executive Officer
Sale $23,750
15 Feb 2005
Joseph K Belanoff
Chief Executive Officer
Sale $22,704
25 Jan 2005
Joseph K Belanoff
Chief Executive Officer
Sale $17,019
19 Jan 2005
Joseph K Belanoff
Chief Executive Officer
Sale $15,000
5 Jan 2005
Joseph K Belanoff
Chief Executive Officer
Sale $57,900
7 Dec 2004
Joseph K Belanoff
Chief Executive Officer
Sale $16,884
3 Nov 2004
Joseph K Belanoff
Chief Executive Officer
Sale $44,208
1 Nov 2004


Corcept Therapeutics Inc executives and stock owners

Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: